Sugi Predict

Sugi Predict / Compounds / SCHEMBL4334610

SCHEMBL4334610

SCHEMBL4334610

CN(C)[C@@H]1CCN(c2cc(N3CCC(c4ccc(Cl)cc4)CC3)c(F)cc2/C=N/NC(N)=S)C1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MCHR1 Q99705 3/20 0.42
▸ FPR1 P21462 2/20 0.40
▸ FPR2 P25090 2/20 0.40
▸ ALDH1A1 P00352 6/20 0.39
▸ MAPT P10636 4/20 0.39
▸ GAA P10253 3/20 0.39
▸ SMN1; SMN2 Q16637 3/20 0.39
▸ ALOX12 P18054 2/20 0.39
▸ MAOB P27338 1/20 0.35
▸ WDR5 P61964 2/20 0.34
▸ LMNA P02545 2/20 0.33
▸ HPGD P15428 2/20 0.33
▸ HTT P42858 2/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.32
▸ KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4334612 1.00 MCHR1 (0.42) MCHR1FPR1FPR2ALDH1A1MAPT
SCHEMBL4336696 0.93 MAOB (0.36) MCHR1FPR1FPR2ALDH1A1MAPT
SCHEMBL4336693 0.93 MAOB (0.36) MCHR1FPR1FPR2ALDH1A1MAPT
SCHEMBL4333920 0.92 MAOB (0.40) MCHR1FPR1FPR2ALDH1A1MAPT
SCHEMBL4333914 0.92 MAOB (0.40) MCHR1FPR1FPR2ALDH1A1MAPT
SCHEMBL4326223 0.91 ALDH1A1 (0.40) MCHR1FPR1FPR2ALDH1A1MAPT
SCHEMBL4330369 0.91 ALDH1A1 (0.40) MCHR1FPR1FPR2ALDH1A1MAPT
SCHEMBL4329395 0.91 ALDH1A1 (0.40) MCHR1FPR1FPR2ALDH1A1MAOB
SCHEMBL4329391 0.91 ALDH1A1 (0.40) MCHR1FPR1FPR2ALDH1A1MAOB
SCHEMBL4327204 0.91 MAPT (0.43) MCHR1FPR1FPR2ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-11-19 — — US disclosed
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-11-19 — — US disclosed
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-11-19 — — US disclosed
US-7521062-B2 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2009-04-21 — — US disclosed
US-7521062-B2 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2009-04-21 — — US disclosed
US-7521062-B2 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2009-04-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators MAVS, IRF3, HAVCR2 MCHR1 2909/4885FPR1 1591/4885FPR2 2277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.